AHK-Cu

What is AHK-Cu?

AHK-Cu is a copper-chelated tripeptide consisting of the sequence L-alanyl-L-histidyl-L-lysine bound to a copper(II) ion. In cosmetic and dermatologic literature, it is also referenced as Copper Tripeptide-3 (with Copper Tripeptide-1 being GHK-Cu). The copper coordinates through the histidine-imidazole nitrogen, the terminal alanine amine, and an adjacent peptide-bond nitrogen, producing a stable square-planar complex analogous in architecture to GHK-Cu but with alanine in place of glycine at the N-terminus. That single residue swap is associated with a distinct biological profile: where GHK-Cu's reputation sits mostly in collagen and wound-healing biology, AHK-Cu's published work is dominated by hair follicle effects — dermal papilla cell proliferation, follicle elongation, and anti-apoptotic signaling — from the foundational Pyo et al. 2007 study. AHK-Cu is the research-grade copper complex itself; Pal-AHK (palmitoyl tripeptide-28) is the lipidated cosmetic-ingredient form used for transdermal delivery.

What AHK-Cu Is Investigated For

AHK-Cu is best understood as the hair-focused cousin of GHK-Cu. The mechanistic case for its hair-follicle activity is interesting and well-characterized at the molecular level — Pyo et al. demonstrated that AHK-Cu at picomolar to nanomolar concentrations stimulated human hair follicle elongation ex vivo and dermal papilla cell proliferation in vitro, with a clear anti-apoptotic signature (elevated Bcl-2/Bax ratio, substantial reductions in cleaved caspase-3 and cleaved PARP), plus VEGF upregulation and TGF-β1 suppression in fibroblasts. The core limitation is that this foundational work is a single study from a single research group, independent replication is thin, no in vivo animal hair-growth models have been published, and no human clinical trial exists for AHK-Cu as a standalone for any endpoint. Commercial products for scalp use often combine AHK-Cu or its palmitoylated form Pal-AHK with other copper peptides, caffeine, biotin, or minoxidil — none of those combinations have controlled human efficacy data comparing the peptide to placebo. For androgenetic alopecia, FDA-approved minoxidil and finasteride have an incomparably stronger evidence base.

History & Discovery

AHK-Cu emerged from structure-activity research on the copper-tripeptide family in the 1990s and 2000s, following Loren Pickart's original work on GHK-Cu from the 1970s. Investigators exploring which elements of the GHK sequence were essential for copper binding and biological activity found that the histidine-lysine C-terminus, which provides the copper-coordinating imidazole and the positive charge for membrane interaction, tolerated substitutions at the N-terminus — glycine (GHK), alanine (AHK), and other residues could all form stable copper complexes with related but non-identical biology. The AHK variant was not the primary focus of most early copper-peptide work, but it gained a distinct identity after Pyo et al.'s 2007 paper demonstrated effects on human hair follicles and dermal papilla cells that GHK-Cu had not been prominently associated with, giving the cosmetic industry a differentiated 'hair' copper peptide to sit alongside the 'skin' copper peptide GHK-Cu. Palmitoylation came later as part of the broader cosmetic-peptide delivery toolkit: conjugating a C16 palmitoyl chain to a peptide N-terminus improves stratum corneum penetration enough to make a small hydrophilic peptide viable as a topical active. Pal-AHK (INCI palmitoyl tripeptide-28, also listed historically as palmitoyl tripeptide-3) became the cosmetic-ingredient workhorse derived from AHK. Independent peer-reviewed replication of the Pyo et al. findings in AHK-Cu or Pal-AHK remains limited, and the peptide has moved into the over-the-counter hair-product market well ahead of the clinical evidence base that would be typical for a regulated drug.

How It Works

AHK-Cu appears to support hair follicle cells by keeping them alive and dividing. In lab studies it tips the balance of survival proteins inside dermal papilla cells (the cells at the base of each hair follicle that control growth) — increasing the pro-survival Bcl-2 signal, decreasing the pro-death Bax signal, and reducing the execution proteins that run the cell-death program. It also nudges fibroblasts in the skin to make more VEGF (which supports blood vessel formation and nutrient delivery to follicles) and less TGF-β1 (which normally pushes hair follicles toward the resting phase). The copper ion is central to the complex — it is not just a delivery vehicle but part of the active molecule.

The key mechanistic work on AHK-Cu comes from Pyo and colleagues' 2007 in vitro and ex vivo study on human hair follicles and cultured dermal papilla cells (DPCs). At concentrations of 10^-12 to 10^-9 M, AHK-Cu stimulated ex vivo hair follicle elongation and DPC proliferation in culture. At the molecular level, AHK-Cu elevated the Bcl-2/Bax ratio — upregulating the anti-apoptotic mitochondrial protein Bcl-2 while downregulating the pro-apoptotic Bax — and reduced cleaved caspase-3 by 42.7% and cleaved PARP by 77.5% at 10^-9 M, indicating substantial inhibition of the intrinsic apoptosis pathway in DPCs. In dermal fibroblasts, AHK-Cu stimulated proliferation, elevated VEGF secretion, decreased TGF-β1 secretion, and was reported to increase collagen type I production up to 300% compared to controls. TGF-β1 is a known catagen-inducing factor that drives hair follicles out of the anagen (growth) phase; its suppression by AHK-Cu is mechanistically consistent with prolonged anagen activity. The copper ion is integral to the coordination complex, binding through the histidine imidazole, the terminal amine, and adjacent peptide-bond nitrogens. Receptor-level binding data for AHK-Cu specifically is not established; whether effects are mediated by a cell-surface copper-peptide receptor, through intracellular release of copper and the tripeptide, or through a combination, remains uncharacterized.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about AHK-Cu:

• 01Controlled human clinical trials — no published RCTs exist for AHK-Cu or Pal-AHK for hair growth, skin anti-aging, or any other endpoint. All efficacy claims are extrapolations from preclinical work.
• 02Independent replication of the foundational Pyo et al. 2007 findings — most marketing and mechanistic claims trace back to this single study from a single research group. Peer-reviewed independent replication is essential for treating the mechanism as established.
• 03In vivo animal hair-growth studies — no published rodent or other in vivo hair-growth models have been completed for AHK-Cu, a notable gap given the strength of ex vivo and in vitro claims.
• 04Whether the palmitoylated form (Pal-AHK) retains AHK-Cu's biological activity at the cellular level — this is assumed but not directly demonstrated. Whether Pal-AHK cleaves to release free AHK / AHK-Cu intracellularly or acts as an intact molecule at the cell surface is uncharacterized.
• 05Receptor-level characterization — no surface-receptor binding target for AHK-Cu has been identified; the cell-entry mechanism and intracellular trafficking of the copper complex are not well mapped.
• 06Real-world skin penetration from commercial formulations — delivery of AHK-Cu or Pal-AHK to viable dermis and dermal papilla cells from typical topical products is not quantified.
• 07Head-to-head comparisons with minoxidil, finasteride, or other cosmetic hair ingredients at equivalent use conditions — almost all AHK-Cu marketing is built on mechanism rather than comparative human efficacy.

Forms & Administration

AHK-Cu is available in two broad formats. As a research-grade blue powder it is supplied for topical reconstitution into serums, scalp tonics, and mesotherapy cocktails; compounding and cosmetic chemists will solubilize it in water or low-alcohol vehicles, typically at sub-percent concentrations. The palmitoylated form Pal-AHK is the version used in over-the-counter cosmetic formulations because the lipid conjugation improves stratum corneum penetration. Injectable or systemic AHK-Cu is not an established clinical category in humans. Some scalp mesotherapy and microneedling protocols use topical AHK-Cu solutions to improve superficial dermal delivery, but controlled efficacy evidence for that approach is absent.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

AHK-Cu is not FDA-approved for any medical indication. Topical use is regulated under cosmetic rather than drug frameworks. Hair-loss claims that cross into drug-claim territory ('treats alopecia,' 'reverses balding') are not permitted on cosmetic labels and are not supported by clinical trial evidence for this peptide.

Timeline of Effects

Common Questions

Who AHK-Cu Is NOT For

Drug & Supplement Interactions

Documented pharmacological drug interactions for topical AHK-Cu are minimal. Systemic absorption from typical topical cosmetic use is low, and the copper-tripeptide complex is not expected to reach clinically relevant plasma levels or interact with oral or injected medications. The interaction space that actually matters is topical layering. AHK-Cu is generally compatible with other peptide actives, niacinamide, hyaluronic acid, and gentle hydrating scalp tonics. Co-formulation with other copper tripeptides (GHK-Cu, Pal-GHK) is common in multi-peptide products, though there is a theoretical concern that competing copper-binding peptides could affect each other's coordination state — clinical relevance is unclear. High-concentration L-ascorbic acid (vitamin C) and strong AHA/BHA exfoliants can destabilize copper-peptide complexes if applied in the same layer or immediately after, so spacing these to different times of day is sensible. Pairing with topical minoxidil in scalp routines is a common over-the-counter product design; no specific interaction has been documented but the combination has not been formally studied. For hair-loss patients on FDA-approved therapies (oral finasteride, oral minoxidil, dutasteride), there is no documented interaction with AHK-Cu at the level of topical cosmetic exposure, but AHK-Cu should not be relied on as a substitute for evidence-based pharmacologic options.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions